Neurodegenerative disease can make people feel like they have no control over their own bodies, their own minds, their own lives.
Over 50 million people worldwide suffer from the neurodegenerative condition epilepsy. Despite taking multiple medications, more than 30% of these people continue to have seizures.
Our mission at Insero is to develop novel therapies for neurodegenerative disease that will help patients better manage their condition and achieve greater control over their lives. We start with compounds found in nature with the goal of developing safe and effective therapies for patients with neurodegenerative disease.
Founded in 2011, Insero Health is a clinical stage company that discovers and develops small molecule therapies derived from natural products to address significant unmet needs in neurological diseases. Insero is a spinout of Harvard Medical School and has licensed technology from Yale University to support its clinical, research and discovery programs.
The company’s initial target is epilepsy, a debilitating seizure disorder that affects approximately 3 million people in the United States and over 50 million people worldwide. Nearly one-third of all epilepsy patients continue to have uncontrolled seizures despite being on multiple medications, seriously compromising their ability to work and their quality of life. In addition, many patients whose seizures are currently well controlled are subject to serious side effects, including somnolence, dizziness and cognitive dysfunction.